Premicroalbuminuria in women with polycystic ovary syndrome: A metabolic risk marker

Endocrine Practice

Volumn 14, Issue 2, 2008, Pages 193-200

  Patel, Arti A ^a   Bloomgarden, Zachary T ^a   Futterweit, Walter ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; CREATININE; BIOLOGICAL MARKER; CREATINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MICROALBUMINURIA; OVARY POLYCYSTIC DISEASE; PREMENOPAUSE; PREMICROALBUMINURIA; PREVALENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; ALBUMINURIA; MIDDLE AGED; PATHOLOGY; RISK FACTOR; URINE;

ADULT; ALBUMINURIA; BIOLOGICAL MARKERS; BLOOD PRESSURE; CREATINE; FEMALE; HUMANS; METABOLIC SYNDROME X; MIDDLE AGED; POLYCYSTIC OVARY SYNDROME; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 45849086963     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.2.193     Document Type: Article

References (41)

1. Franks S. Polycystic ovary syndrome [published correction appears in N Engl J Med. 1995;333:1435]. N Engl J Med. 1995;333:853-861.
2. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999;84:1897-1899.
3. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165-1174.
4. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand. 1992;71:599-604.
5. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999;22:141-146.
6. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999;84:165-169.
7. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol. 2000;20:2414-2421.
8. Orio F Jr, Palomba S, Spinelli L, et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study [published correction appears in J Clin Endocrinol Metab. 2004;89:5621]. J Clin Endocrinol Metab. 2004;89:3696-3701.
9. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia. 1983;25:496-501.
10. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion: an independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol. 1999;19:1992-1997.
11. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002;7:35-43.
12. Lambers Heerspink HJ, Brinkman JW, Bakker SJ, Gansevoort RT, de Zeeuw D. Update on microalbuminuria as a biomarker in renal and cardiovascular disease. Curr Opin Nephrol Hypertens. 2006;15:631-636.
13. Gerstein HC, Mann JF, Yi Q, et al (Hope Study Investigators). Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-426.
14. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation. 2004;110:32-35.
15. Arnlöv J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005;112:969-975.
16. Liese AD, Hense HW, Döring A, Stieber J, Keil U. Microalbuminuria, central adiposity and hypertension in the non-diabetic urban population of the MONICA Augsburg survey 1994/95. J Hum Hypertens. 2001;15:799-804.
17. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167-174.
18. Choi HS, Ryu SH, Lee KB. The relationship of microalbuminuria with metabolic syndrome. Nephron Clin Pract. 2006;104:C85-C93.
19. Parvanova AI, Trevisan R, Iliev IP, et al. Insulin resistance and microalbuminuria: a cross-sectional, case-control study of 158 patients with type 2 diabetes and different degrees of urinary albumin excretion. Diabetes. 2006;55:1456-1462.
20. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism. 2003;52:908-915.
21. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:1929-1935.
22. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol. 2005;106:131-137.
23. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: toward a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GH, eds. Polycystic Ovary Syndrome: Current Issues in Endocrinology and Metabolism. Boston, MA: Blackwell Scientific, 1992: 377-384.
24. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Obesity Technical Report Series 894. Geneva, Switzerland: World Health Organization, 2000.
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
26. Genuth S, Alberti KG, Bennett P, et al (Expert Committee on the Diagnosis and Classification of Diabetes Mellitus). Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-3167.
27. Cirillo M, Senigalliesi L, Laurenzi M, et al. Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: the Gubbio Population Study. Arch Intern Med. 1998;158:1933-1939.
28. de Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL (PREVEND Study Group). Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord. 2002;26(Suppl 4):S21-S24.
29. Barzilay JI, Peterson D, Cushman M, et al. The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study. Am J Kidney Dis. 2004;44:25-34.
30. Wild RA. Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med. 1995;98:27S-32S.
31. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997;96:2520-2525.
32. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 1983;57:356-359.
33. Winocour PH, Harland JO, Millar JP, Laker MF, Alberti KG. Microalbuminuria and associated cardiovascular risk factors in the community. Atherosclerosis. 1992;93:71-81.
34. Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Insulin sensitivity in clinically healthy individuals with microalbuminuria. Atherosclerosis. 1996;119:69-76.
35. Zavaroni I, Bonini L, Gasparini P, et al. Dissociation between urinary albumin excretion and variables associated with insulin resistance in a healthy population. J Intern Med. 1996;240:151-156.
36. Jager A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Microalbuminuria is strongly associated with NIDDM and hypertension, but not with the insulin resistance syndrome: the Hoorn Study. Diabetologia. 1998;41:694-700.
37. Mykkänen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes. 1998;47:793-800.
38. De Cosmo S, Minenna A, Ludovico O, et al. Increased urinary albumin excretion, insulin resistance, and related cardiovascular risk factors in patients with type 2 diabetes: evidence of a sex-specific association. Diabetes Care. 2005;28:910-915.
39. Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:1273-1276.
40. Bloomgarden ZT. Measures of insulin sensitivity. Clin Lab Med. 2006;26:611-633, vi.
41. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh HC, Futterweit W. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol. 2007;4:496-501.